Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

2010/02/09 by Wah-Seng Lim, Paul G. Tardi, Paul Tardi +8 · 2 citations
Materials Science · Medicine · #Acute Lymphoblastic Leukemia research #Acute Myeloid Leukemia Research #Nanoparticle-Based Drug Delivery

paper · doi:10.1016/j.leukres.2010.01.015

openalex publication_date 2010/02/09 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/26

Cited by

• AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group
• Diagnosis and treatment of therapy-related acute myeloid leukemia